Background The benefit of an implantable cardioverter–defibrillator (ICD) in patients with
symptomatic systolic heart failure caused by coronary artery disease has been well
documented. However, the evidence for a benefit of prophylactic ICDs in patients with
systolic heart failure that is not due to coronary artery disease has been based primarily on
subgroup analyses. The management of heart failure has improved since the landmark ICD
trials, and many patients now receive cardiac resynchronization therapy (CRT). Methods In a …

Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, Jensen G, Hildebrandt P,
Steffensen FH, Bruun NE, Eiskjær H, Brandes A, Thøgersen AM, Gustafsson F, Egstrup K,
Videbæk R, Hassager C, Svendsen JH, Høfsten DE, Torp-Pedersen C, Pehrson S; DANISH
Investigators.